STALE?Report written 7 days ago · at $49.37entry levels may be stale — re-check before acting

SRRK

SpeculativeMID CAP

Scholar Rock Holding Corporation · NASDAQ · Healthcare / Biotechnology

$49.37

▲ 0.40%

MCap $6.22B

Roughly flat since the Aug 13 report ($49.10) — the PDUFA catalyst already fired: FDA approved ISEMBYLD on Sep 11, 2026, ahead of the Sep 30 action date

BusinessSingle-asset biotech, now commercial-stage · ISEMBYLD (apitegromab-mstn) — first and only muscle-targeted treatment for SMA, FDA-approved Sep 11, 2026

Thesis

REFRESH (prior report Aug 13, 2026) — CATALYST RESOLVED: the FDA approved ISEMBYLD (apitegromab-mstn) on Sep 11, 2026 — the first and only muscle-targeted SMA treatment, ahead of its Sep 30 PDUFA date. Jefferies raised its target to $65 (Buy) on the approval. Despite the positive outcome, the stock is roughly flat since Aug ($49.10 to $49.37) — the binary-event risk premium simply came out of the price rather than driving a fresh pop, consistent with a well-anticipated approval. The story is now commercial-execution, not regulatory-binary: the next catalyst is Q3 2026 earnings, the first quarter of real launch metrics. Consensus (Jefferies-anchored) $65 implies +31.7% upside from $49.37. Base case (+20%) is above the core lane's realized 14d P75 of +6.6% — the gap reflects a multi-quarter commercial-launch horizon, not optimism bias.

📝 Primary Verdict · Core Holding

BUYSpeculative

Measured median at-catalyst return across the core lane is -6.9% (n=54) — buying at today's $49.37 is not the default entry; the $43-45 pre-earnings dip is preferred. The regulatory binary has already resolved favorably (approved Sep 11); the remaining trade is a commercial-launch execution story, which is a lower-variance but also lower-adrenaline setup than the original PDUFA play.

73

score / 100 ⓘ

⚡ Catalyst

📊 Q3 2026 Earnings — First ISEMBYLD Launch Metrics~45 DAYS

First quarterly print since the Sep 11 FDA approval — the market's first real read on payer/formulary uptake and prescription volume for a muscle-targeted SMA drug. Exact date not yet company-confirmed; estimated from typical biotech reporting cadence.

~Nov 2026

🎯 Entry Point

Entry 1

$49.37

Current priceNow

Entry 2PREFERRED

$43–45

Pre-earnings dip zoneIf dips

Entry 3

$38.00

Deep dip — would imply the market is pricing a weak launchDeep dip only

✅ Take Profit

TP1

Base case — steady early launch uptake

$59.24

+20%

TP2

Bull case — near Jefferies' post-approval target

$65.17

+32%

TP3 🌙

Moon case — launch uptake beats expectations, target upgrades follow

$74.06

+50%

🔴 Stop Loss

Tight Stop

Wider than the earnings_beat bucket's medianMAE (-9.6%, n=42)

$42.46

-14%

Hard Stop

Near the pre-approval deep-dip zone — signals the launch thesis is breaking

$37.03

-25%

Risk / Reward

Tight stop vs TP2, off current price

2.3 : 1

⚠ Fair R/R

📅 Estimate Date

FDA Approval (realized)

ISEMBYLD approved — ahead of the Sep 30 PDUFA date

Sep 11, 2026

Q3 2026 Earnings

First commercial-launch metrics quarter

~Nov 2026

Manufacturing Site Readiness

Second fill-finish facility supports supply as launch scales

Ongoing

📈 Stock Timeline

2 snapshots · Aug 13 → Sep 29

Score

▼ 2

64

Aug 13Sep 29

TP2 Target

▼ 5

$65.17

Aug 13Sep 29

Rank

▲ 9

#14

Aug 13Sep 29

📈 Possible Up % — Scenario Spread

Bear

-30%

$34.56

Base

+20%

$59.24

Bull

+32%

$65.17

Moon

+50%

$74.06

← downsideupside →

🏛️ Fed / Macro Risk — MEDIUM

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook

Fed hiked to 3.75-4.00% on Sep 16, 2026 (first hike since 2023); next FOMC Oct 27-28, 2026 — before the estimated Q3 earnings window, adding some macro noise into the print.

Inflation

Inflation-driven hike; the FDA approval materially reduces Scholar Rock's near-term financing dependency versus the pre-approval state, which cushions the macro exposure somewhat.

Sector Impact

Commercial-stage biotech with an approved, differentiated drug is less rate-sensitive than pre-approval, cash-burning names — the story is now about launch execution, which is largely idiosyncratic.

Summary

MEDIUM macro risk — approval reduces financing urgency, but Scholar Rock is still pre-meaningful-revenue and will eventually need the capital markets to cushion the launch ramp; a hawkish Fed raises that future cost.

🎯 Analyst Targets

Wall Street price targets vs the current price — cross-check our TP levels

Jefferies

Buy$65+32%

BMO Capital

Outperform$70+42%

BofA Securities

Buy$58+17%

Truist Securities

Buy$55+11%

current price $49.37

🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

SRRK⚡ MixedSep 2026

+0.5%

in 1 day

FDA approves ISEMBYLD (apitegromab) for SMA — first and only muscle-targeted treatment

The approval itself barely moved the stock, confirming it was well-anticipated — the real re-rating opportunity is now the launch data, not the approval headline

AGIO✅ GoodDec 2025

+19.97%

in 1 day

AQVESME (mitapivat) FDA approval for thalassemia anemia — comparable rare-hematology/neuromuscular approval pattern

Shows the wider range of possible approval-day reactions in rare-disease biotech — SRRK's muted move sits at the low end of that range

⚡ Optional Layer · Tactical Overlay

🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-14% / -14%) only when trading the earnings spot — not for the core holding (use the -14% / -25% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern

+5% to +10%1-2 weeks before the print

Now that the regulatory binary has resolved, SRRK should behave more like a standard commercial-stage biotech into its next print — modest pre-earnings drift on launch-metrics anticipation

🎲Historical Post-Catalyst Move

✅ Catalyst Winavg +15%

range: +10% to +25%· N/A — first commercial quarter

No SRRK-specific commercial-launch print exists yet (this is the first one). Proxied from general small-cap biotech launch-quarter beats and from the muted approval-day reaction itself, which suggests the stock will react to concrete uptake numbers more than headline sentiment.

❌ Catalyst Missavg -18%

range: -10% to -25%· N/A — first commercial quarter

Rare-disease drug launches that miss uptake expectations in their first reporting quarter typically see sharp de-rates as the market recalibrates peak-sales assumptions; no SRRK-specific precedent exists yet.

💼Spot Position Sizing

How the recommended % is derived

4%

of portfolio

Regulatory risk is now off the table (approved), but this is a single-asset biotech entering its first commercial quarter — size moderately for launch-execution uncertainty

🛑Stop Loss · Spot Trade

Spot cut-loss levels — separate from the core holding

Before Catalyst

-14%($42.46)

Below this, pre-print sentiment on launch uptake has turned negative

After Catalyst (Bad Result)-14%

If the first commercial quarter shows weak uptake, exit rather than wait for a second data point

📎 Sources

https://www.sec.gov/Archives/edgar/data/0001727196/000110465926107273/tm2625362d1_ex99-1.htm https://www.biospace.com/press-releases/scholar-rock-announces-fda-approval-of-isembyld-apitegromab-mstn-the-first-and-only-muscle-targeted-treatment-for-children-and-adults-with-spinal-muscular-atrophy-sma https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-announces-fda-review-apitegromab-biologics-license https://finance.yahoo.com/healthcare/articles/scholar-rock-announces-fda-approval-222500403.html https://www.cnbc.com/2026/09/16/fed-rate-decision-september-2026.html

Generated 2026-09-29 · Not financial advice